Laboratorios Farmaceuticos ROVI (ROVI), a Spanish specialty healthcare company, reportedly expects to launch a biosimilar enoxaparin, a low-molecular-weight heparin (LMWH) product, in the European marketplace by the end of 2017. ROVI requested marketing authorization for its biosimilar product in Europe in 2014.
Laboratorios Farmaceuticos ROVI (ROVI), a Spanish specialty healthcare company, reportedly expects to launch a biosimilar enoxaparin, a low-molecular-weight heparin (LMWH) product, in the European marketplace by the end of 2017. ROVI requested marketing authorization for its biosimilar product in Europe in 2014.
Currently, 2 biosimilars (Inhixa and Thorinane) are approved for use in the European Union (EU) on the basis of their biosimilarity to the reference enoxaparin, Sanofi’s Lenovox. Sanofi’s originator LMWH is approved for use in the United States and in all EU member nations, where it is marketed under the names Clexane, Klexane, and Qualiop, among others. ROVI estimates that worldwide sales of enoxaparin reached $1.8 billion in 2016, and that the European market represented 63% of the total sales value. ROVI says that it seeks to leverage its biosimilar to capture a share of these earnings, particularly in emerging markets.
In the United States, a follow-on enoxaparin was approved by the FDA in 2010. Sandoz’s version of the drug was not, however, approved as a biosimilar, but as a generic. According to the Generics and Biosimilar Initiative, this seeming irregularity is due in part to the fact that the approval process for Sandoz’s product began years before the Biologics Price Competition and Innovation Act was enacted into law.
Furthermore, the originator enoxaparin had not been approved in the United States under a Biologic License Application; according to a recent review in Thrombosis Journal, in the United States, originator LMWHs were classified as drugs under the Abbreviated New Drug Application procedure, as are small-molecule drugs. As such, the FDA approved Sandoz’s product as a generic, not a biosimilar, based on:
However, the European Medicine’s Agency, in its “Guidelines on non-clinical and clinical development of similar biological medicinal products containing low molecular weight heparin,” which came into effect in June of 2017, treats the originator LMWH as a biologic, and treats follow-on products as biosimilars. This approach, according to the Thrombosis Journal review’s authors, has been instituted despite the fact that it “…is more difficult to apply to biological substances arising from extraction from biological sources and/or those for which little clinical and regulatory experience has been gained, like LMWHs, when compared to products that are highly purified and can be thoroughly characterized.” The guidelines hold that evidence for similarity of efficacy should be derived from physicochemical, functional, and pharmacodynamic (PD) comparisons, not necessarily from comparative efficacy trials.
These variations in international approaches to the approval of LMWHs, as well as the complexity of addressing the similarity of products extracted from animal tissue, highlight lingering challenges in the regulation of such treatments, leading many, including the review’s authors, to call upon regulators to require additional safety and efficacy studies for future follow-on LMWH.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.